%0 Journal Article
%T Pazopanib for the treatment of soft-tissue sarcoma
%A Heudel P
%A Cassier P
%A Derbel O
%A Dufresne A
%A Meeus P
%A Thiesse P
%A Ranch¨¨re-Vince D
%A Blay JY
%A Ray-Coquard I
%J Clinical Pharmacology: Advances and Applications
%D 2012
%I Dove Medical Press
%R http://dx.doi.org/10.2147/CPAA.S33195
%X zopanib for the treatment of soft-tissue sarcoma Review (1305) Total Article Views Authors: Heudel P, Cassier P, Derbel O, Dufresne A, Meeus P, Thiesse P, Ranch¨¨re-Vince D, Blay JY, Ray-Coquard I Published Date October 2012 Volume 2012:4 Pages 65 - 70 DOI: http://dx.doi.org/10.2147/CPAA.S33195 Received: 22 April 2012 Accepted: 16 June 2012 Published: 26 October 2012 Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranch¨¨re-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,5 1Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Pathology, Leon Berard Center, Lyon, 5EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, France Abstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.
%K soft-tissue sarcoma
%K pazopanib
%K tyrosine kinase inhibitor
%U https://www.dovepress.com/pazopanib-for-the-treatment-of-soft-tissue-sarcoma-peer-reviewed-article-CPAA